Last Updated on March 21, 2022 by GlobeNewsWire
COPENHAGEN, Denmark, March 21, 2022 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.
The transactions concern the vesting of restricted stock units (RSUs) including matching shares awarded to members of the Company’s Executive Management in 2019 in accordance with the decision by the Board of Directors to defer part of the annual cash bonus related to Executive Management’s performance in 2018 by conversion into RSUs. The three-year vesting period has now expired, and all conditions for release of the shares, including matching shares, have been met.
1.Details of the person discharging managerial responsibilities/person closely associated a)NamePaul Chaplin2.Reason for the notificationa)Position/statusPresident and Chief Executive Officer of Bavarian Nordic A/Sb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBavarian Nordic A/Sb)LEI2138006JCDVYIN6INP514.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type of instrument
Identification code
Shares
DK0015998017
b)Nature of the transactionAcquisition of shares (vesting of restricted stock units)c)Price(s) and volume(s)Price(s)Volume(s) DKK 75.8411,458d)Aggregated information Aggregated volumePrice
11,458
DKK 868,959.00
e)Date of the transaction2022-03-21f)Place of the transactionOutside a trading venue1.Details of the person discharging managerial responsibilities/person closely associated a)NameHenrik Juuel2.Reason for the notificationa)Position/statusExecutive Vice President and Chief Financial Officer of Bavarian Nordic A/Sb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBavarian Nordic A/Sb)LEI2138006JCDVYIN6INP514.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type of instrument
Identification code
Shares
DK0015998017
b)Nature of the transactionAcquisition of shares (vesting of restricted stock units)c)Price(s) and volume(s)Price(s)Volume(s) DKK 75.94966d)Aggregated information Aggregated volumePrice
966
DKK 73,354.00
e)Date of the transaction2022-03-21f)Place of the transactionOutside a trading venue1.Details of the person discharging managerial responsibilities/person closely associated a)NameHenrik Birk2.Reason for the notificationa)Position/statusExecutive Vice President and Chief Operating Officer of Bavarian Nordic A/Sb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBavarian Nordic A/Sb)LEI2138006JCDVYIN6INP514.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type of instrument
Identification code
Shares
DK0015998017
b)Nature of the transactionAcquisition of shares (vesting of restricted stock units)c)Price(s) and volume(s)Price(s)Volume(s) DKK 75.855,482d)Aggregated information Aggregated volumePrice
5,482
DKK 415,800.00
e)Date of the transaction2022-03-21f)Place of the transactionOutside a trading venue
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccine company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN(R), we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.
Contacts
Europe: Rolf Sass Sorensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600
Company Announcement no. 07 / 2022
Attachment
